Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms

Australian and New Zealand Journal of Psychiatry

Volumn 46, Issue 2, 2012, Pages 153-160

  Shifu, Xiao ^a   Haibo, Xue ^a   Guanjun, Li ^a   Chengmei, Yuan ^a   Xia, Li ^a   Chao, Chen ^a   Wu, Helen Zong Ying ^b   Mitchell, Philip ^a   Mingyuan, Zhang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cerebrolysin; effect; risperidone; schizophrenia

Indexed keywords

CEREBROLYSIN; NEUROLEPTIC AGENT; PLACEBO; RISPERIDONE; AMINO ACID; NOOTROPIC AGENT;

ADD ON THERAPY; ADULT; ARTICLE; BLOOD; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; DSM-IV; ELECTROCARDIOGRAM; FEMALE; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL PERFORMANCE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; WECHSLER INTELLIGENCE SCALE; WECHSLER MEMORY SCALE; WEIGHT GAIN; WEIGHT REDUCTION; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; MIDDLE AGED;

ADULT; AGED; AMINO ACIDS; ANTIPSYCHOTIC AGENTS; COGNITION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MEMORY; MIDDLE AGED; NOOTROPIC AGENTS; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84861664174     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867411433213     Document Type: Article

References (30)

1. Alvarez XA, Cacabelos R, Sampedro C, et al. Efficacy and safety of cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of cerebrolysin. European Journal of Neurology. 2011 ; 18 (1). 59-68
2. Amiri A, Noorbala AA, Nejatisafa AA, et al. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Human Psychopharmacology. 2008 ; 23 (2). 79-86
3. Bajenaru O, Tiu C, Moessler, et al. Efficacy and safety of cerebrolysin in patients with hemorrhagic stroke. Journal of Medicine and Life. 2010 ; 3 (2). 137-143
4. Erhart SM, Marder SR, Carpenter WT. Treatment of schizophrenia negative symptoms: future prospects. Schizophrenia Bulletin. 2006 ; 32 (2). 234-237
5. Fleischhacker WW, Eerdkens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Journal of Clinical Psychiatry. 2003 ; 64 (10). 1250-1257
6. Foussias G, Remington G. Antipsychotic and schizophrenia: from efficacy and effectiveness to clinical decision-making. Canadian Journal of Psychiatry. 2010 ; 55 (3). 117-125
7. Galletly C. Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology. 2009 ; 202 (1-3). 259-273
8. Jianu DC, Muresanu DF, Bajenaru O, et al. Cerebrolysin adjuvant treatment in Broca's aphasics following first acute ischemic stroke of the left middle cerebral artery. Journal of Medicine and Life. 2010 ; 3 (3). 297-307
9. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry. 2007 ; 64 (6). 633-647
10. Lahti AC, Weiler MA, Holcomb HH, et al. Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. Neuropsychopharmacology. 2006 ; 31 (1). 221-230
11. Mäkinen J, Miettunen J, Isohanni M, et al. Negative symptoms in schizophrenia: a review. Nordic Journal of Psychiatry. 2008 ; 62 (5). 334-341
12. Minatogawa-Chang TM, Schaufelberger MS, Ayres AM, et al. Cognitive performance is related to cortical grey matter volumes in early stages of schizophrenia: a population-based study of first-episode psychosis. Schizophrenia Research. 2009 ; 113 (2-3). 200-209
13. Mueser KT, McGurk SR. Schizophrenia. Lancet. 2004 ; 4 (9426). 373-390
14. Plosker GL, Gauthier S. Cerebrolysin: a review of its use in dementia. Drugs and Aging. 2009 ; 26 (11). 893-915
15. Radzivil MG, Bashina VM. An effect of long-term cerebrolysin therapy in combination with neuroleptics on behavioural and cognitive disturbances in endogenous childhood autism. Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova. 2006 ; 106 (2). 21-5
16. Riedel M, Spellmann I, Strassnig M, et al. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience. 2007 ; 257 (6). 360-370
17. Rund BR. Is schizophrenia a neurodegenerative disorder?. Nordic Journal of Psychiatry. 2009 ; 63 (3). 196-201
18. Sergi MJ, Green MF, Widmark C, et al. Social cognition and neurocognition: effects of risperidone, olanzapine, and haloperidol. American Journal of Psychiatry. 2007 ; 164: 1585-1591
19. Jiang KD Psychopharmacology. 2007 ) Psychopharmacology, 1st edition. Beijing: People's Medical Publishing House, pp. 303-366. Beijing: People's Medical Publishing House ; 2007: 303-366.
20. Takahashi T, Wood SJ, Soulsby B, et al. Follow-up MRI study of the insular cortex in first-episode psychosis and chronic schizophrenia. Schizophrenia Research. 2009 ; 108 (2-3). 49-56
21. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, 'just the facts' what we know in 2008. 2. Epidemiology and etiology. Schizophrenia Research. 2008 ; 102 (1-3). 1-18
22. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, 'just the facts' 4. Clinical features and conceptualization. Schizophrenia Research. 2009 ; 110 (1-3). 1-23
23. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, 'just the facts' 5. Treatment and prevention. Past, present, and future. Schizophrenia Research. 2010 ; 122 (1-3). 1-23
24. Ubhi K, Rockenstein E, Doppler E, et al. Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of cerebrolysin. Acta Neuropathologica. 2009 ; 117 (6). 699-712
25. Urfer-Parnas A, Mortensen WL, Parnas J. Core of schizophrenia: estrangement, dementia or neurocognitive disorder?. Psychopathology. 2010 ; 43 (5). 300-311
26. Vereshchagin N, Lebedeva NV, Suslina ZA, et al. Mild forms of multiinfarct dementia; effectiveness of cerebrolysin. Sowetskaia Meditsina. 1991 ; 11 (11). 6-8
27. Wei ZH, He QB, Wang H, et al. Meta-analysis: the efficacy of nootropic agent cerebrolysin in the treatment of Alzheimer's disease. Journal of Neural Transmission. 2007 ; 114 (5). 629-634
28. Wong GK, Zhu XL, Poon WS. Beneficial effect of cerebrolysin on moderate and severe head injury patients: result of a cohort study. Acta Neurochir Suppl. 2005 2005 ; 95: 59-60
29. Xiao SF, Yan HQ, Yao PF, et al. Efficacy of FPF 1070 in patients with Alzheimer's disease: a multicenter, randomised, double-blind, placebo-controled trial. Clinical Drug Investigation. 2000 ; 19 (1). 43-53
30. Zhang C, Chopp M, Cui Y, et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. Journal of Neuroscience Research. 2010 ; 15 (88). 3275-3281